Grant: Operating Grant
University of Calgary
$660,400.00
Stimulator of interferon genes (STING)-induced tumour-associated macrophage re-education as a novel strategy for the treatment of lung cancer.
EF 2014-15
Résumé
'Pre-clinical' modeling of human lung cancers in mice having a functionally-intact immune system is essential to discovering how to best stimulate the immunological killing of cancer cells. We propose an interdisciplinary approach to find novel ways with which to promote anti-tumor immunity. We will employ a new class of drugs that are able to activate blood cell components of the immune system within tumors, either alone, or in combination with state-of-the-art radiotherapy, as well as exciting new types of viruses that can infect and stimulate immunity towards cancer. In addition we will use combination treatments, via the use of antibodies shown to boost anti-tumor immunity in the clinic. We will also develop sophisticated technologies in order to image and record the effects of the treatments. Success in any one of the treatment modalities we are proposing could be rapidly translated into the clinic.
Programme
Operating Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
322558
Name
Jirik Frank R
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Stimulator of interferon genes (STING)-induced tumour-associated macrophage re-education as a novel strategy for the treatment of lung cancer.
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$660,400
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Cyclic Dinucleotides; Image Guided Radiation Therapy (Igrt); Imaging Technologies; Immunotherapy/Checkpoint Inhibition; Non-Small Cell Lung Cancer (Nsclc); Oncolytic Viruses; Stimulator Of Interferon Genes (Sting); Syngeneic Models Of Lung Cancer; Transgenic Mice; Tumour-Associated Macrophages
Abstract
'Pre-clinical' modeling of human lung cancers in mice having a functionally-intact immune system is essential to discovering how to best stimulate the immunological killing of cancer cells. We propose an interdisciplinary approach to find novel ways with which to promote anti-tumor immunity. We will employ a new class of drugs that are able to activate blood cell components of the immune system within tumors, either alone, or in combination with state-of-the-art radiotherapy, as well as exciting new types of viruses that can infect and stimulate immunity towards cancer. In addition we will use combination treatments, via the use of antibodies shown to boost anti-tumor immunity in the clinic. We will also develop sophisticated technologies in order to image and record the effects of the treatments. Success in any one of the treatment modalities we are proposing could be rapidly translated into the clinic.
Competitiondate
201503
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Jirik, Frank R
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $660,400~ $0~
